Research location
Hamden
Connecticut, United States
Advertisement
Research activity in Hamden
Connecticut, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 131 trials and 133 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Hamden
131 linked trials · page 1 of 3A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 · 2026-04-13 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 · 2025-12-15 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation
RECRUITING
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung CancerNCT04210492 · 2020-08-26 · 1 site observation
RECRUITING
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityNCT07497880 · 2026-04-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979 · 2025-12-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · 2025-03-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · 2024-12-12 · 1 site observation
TERMINATED
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108 · 2024-01-10 · 1 site observation
COMPLETED
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 · 2023-11-22 · 1 site observation
COMPLETED
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · 2023-11-10 · 1 site observation
COMPLETED
Tka Assay for CDK4/6iNCT06572800 · 2023-09-05 · 1 site observation
COMPLETED
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430 · 2023-07-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608 · 2023-03-13 · 1 site observation
COMPLETED
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)NCT05634746 · 2022-12-29 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily InjectionsNCT05462756 · 2022-08-11 · 1 site observation
COMPLETED
Infrared Wraps Effect on Oxygenation of Diabetics Arm, Feet and Lower LegNCT04460612 · 2021-05-26 · 1 site observation
COMPLETED
Eversense® Non-adjunctive Use Post Approval StudyNCT04836546 · 2021-04-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialNCT04402788 · 2021-01-07 · 1 site observation
SUSPENDED
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)NCT04605991 · 2020-11-04 · 1 site observation
COMPLETED
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerNCT04214262 · 2020-08-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerNCT04155034 · 2020-05-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)NCT04281108 · 2020-01-30 · 1 site observation
COMPLETED
Gan & Lee Evaluation of New Biosimilar for Type 1 LisproNCT04254380 · 2019-12-04 · 1 site observation
WITHDRAWN
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 DiabetesNCT03987919 · 2019-07-30 · 1 site observation
COMPLETED
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNCT03488693 · 2018-10-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO StudyNCT03687827 · 2018-10-02 · 1 site observation
COMPLETED
Study of BHV-4157 in Alzheimer's DiseaseNCT03605667 · 2018-07-31 · 1 site observation
COMPLETED
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450 · 2018-07-13 · 1 site observation
COMPLETED
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile InfectionNCT03497806 · 2018-05-01 · 1 site observation
COMPLETED
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsNCT03434119 · 2018-02-20 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 2018-02-01 · 1 site observation
TERMINATED
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant AsthmaNCT03358147 · 2017-12-13 · 1 site observation
COMPLETED
Gan & Lee Insulin Glargine Target Type (1) Evaluating ResearchNCT03371082 · 2017-10-31 · 1 site observation
COMPLETED
Gan & Lee Insulin Glargine Target Type (2) Evaluating ResearchNCT03371108 · 2017-10-31 · 1 site observation
COMPLETED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01NCT03285308 · 2017-09-29 · 1 site observation
TERMINATED
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. DiffNCT03110133 · 2017-05-08 · 1 site observation
COMPLETED
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)NCT02990806 · 2017-01-19 · 1 site observation
COMPLETED
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDNCT02766608 · 2016-05-31 · 1 site observation
COMPLETED
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET ExtensionNCT02586909 · 2016-04-26 · 1 site observation
TERMINATED
Anti-VEGF Treatment for Prevention of PDR/DMENCT02634333 · 2016-01-01 · 1 site observation
COMPLETED
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET StudyNCT02585934 · 2015-10-01 · 1 site observation
COMPLETED
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.